The Food and Drug Administration (FDA) on Friday postponed a Feb. 15 meeting of its Vaccines and Related Biological Products Advisory Committee to discuss the Pfizer-BioNTech COVID-19 vaccine for children ages 6 months to 5 years and said the meeting likely will occur later this spring.
FDA officials said the delay will allow more time to review data on a third dose and help decide whether three doses should be considered as part of its decision on emergency use authorization (EUA).
